株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

脳腫瘍 - パイプライン製品の分析

Brain Cancer - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 229723
出版日 ページ情報 英文 311 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
脳腫瘍 - パイプライン製品の分析 Brain Cancer - Pipeline Review, H2 2015
出版日: 2015年10月21日 ページ情報: 英文 311 Pages
概要

脳腫瘍は、癌細胞(悪性)が脳組織に発生する脳の疾患です。危険因子は、喫煙、放射線被曝、ウイルス感染(HIV)が挙げられます。最もよく見られる症状は、脱力感、歩行困難、痙攣、頭痛です。それ以外の一般的な症状は、悪心、嘔吐、視界不良、または注意力・思考力・記憶力・言語・人格の変化が見られます。

当レポートでは、脳腫瘍に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

脳腫瘍の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Neuralstem, Inc.
  • Basilea Pharmaceutica AG
  • Bionomics Limited
  • Critical Outcome Technologies Inc.
  • Prana Biotechnology Limited
  • e-Therapeutics plc
  • AngioChem Inc.
  • Merrimack Pharmaceuticals, Inc.
  • Stemline Therapeutics, Inc.
  • TVAX Biomedical, Inc.
  • Kinex Pharmaceuticals, LLC
  • to-BBB technologies BV
  • Nuvilex, Inc.
  • DEKK-TEC, Inc.
  • TAU Therapeutics, LLC
  • EGEN, Inc.
  • CureFAKtor Pharmaceuticals. LLC
  • Immune Pharmaceuticals, Inc.
  • Oncology Research International Limited

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • verubulin
  • TVI-Brain-1
  • 2B3-101
  • pritumumab
  • dexanabinol
  • DM-CHOC-PEN
  • MDNA-55
  • KX-02
  • COTI-2
  • BAL-27862
  • irinotecan sucrosofate liposomal
  • SL-302
  • BNC-105
  • ANG-1007
  • EGEN-001
  • ANG-1009
  • TTL-1177
  • CFAK-C4
  • NSI-566
  • KX-02
  • CFAKY-15
  • PBT-519
  • JRP-890
  • JRP-980
  • STE-301
  • STE-401
  • Cancer Vaccine
  • Triaryl NADPH Oxidase Inhibitor
  • STE-101
  • ONC-201
  • ORIL-007
  • Methoxynaphthylfenoterol
  • MSC/dTRAIL
  • SL-301
  • Cannabidiol For Pancreatic Cancer And Brain Cancer
  • Brain Cancer Program
  • Halistatin-3

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC6838IDB

Summary

Global Markets Direct's, 'Brain Cancer - Pipeline Review, H2 2015', provides an overview of the Brain Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Brain Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Brain Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Brain Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Brain Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Brain Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Brain Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Brain Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Brain Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Brain Cancer - Overview
    • Pipeline Products for Brain Cancer - Comparative Analysis
  • Brain Cancer - Therapeutics under Development by Companies
  • Brain Cancer - Therapeutics under Investigation by Universities/Institutes
  • Brain Cancer - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Brain Cancer - Products under Development by Companies
  • Brain Cancer - Products under Investigation by Universities/Institutes
  • Brain Cancer - Companies Involved in Therapeutics Development
    • 2-BBB Medicines BV
    • AbbVie Inc.
    • Actinium Pharmaceuticals, Inc.
    • AngioChem Inc.
    • Arrien Pharmaceuticals, LLC
    • BeiGene(Beijing) Co.,Ltd
    • Berg, LLC
    • biOasis Technologies Inc.
    • Boehringer Ingelheim GmbH
    • Bristol-Myers Squibb Company
    • Cavion LLC
    • Critical Outcome Technologies Inc.
    • CureFAKtor Pharmaceuticals, LLC
    • Diffusion Pharmaceuticals LLC
    • e-Therapeutics Plc
    • Exelixis, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Hutchison MediPharma Limited
    • Komipharm International Co., Ltd.
    • Lipocure Ltd.
    • Medicenna Therapeutics, Inc
    • MEI Pharma, Inc.
    • NatureWise Biotech & Medicals Corporation
    • Nektar Therapeutics
    • Nerviano Medical Sciences S.r.l.
    • Novartis AG
    • Novogen Limited
    • Oncology Research International Limited
    • Oncolytics Biotech Inc.
    • Oncothyreon Inc.
    • Pfizer Inc.
    • Philogen S.p.A.
    • Phosplatin Therapeutics LLC
    • Prana Biotechnology Limited
    • Progenics Pharmaceuticals, Inc.
    • Puma Biotechnology, Inc.
    • Radius Health, Inc.
    • Sanofi
    • Spectrum Pharmaceuticals, Inc.
    • Stemline Therapeutics, Inc.
    • Takeda Pharmaceutical Company Limited
    • Tocagen Inc.
    • ViraTherapeutics GmbH
    • Zymeworks Inc.
  • Brain Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile
    • (topotecan hydrochloride + vincristine sulfate) - Drug Profile
    • 2B3-101 - Drug Profile
    • Actimab-Br - Drug Profile
    • afatinib dimaleate - Drug Profile
    • ANG-1005 - Drug Profile
    • ANG-4043 - Drug Profile
    • ARN-7016 - Drug Profile
    • BGBA-317 - Drug Profile
    • BT-2111 - Drug Profile
    • cabazitaxel - Drug Profile
    • cabozantinib s-malate - Drug Profile
    • Cell Therapy to Target CD133 for Refractory and Relapsed Malignancies - Drug Profile
    • ceritinib - Drug Profile
    • CFAKC-4 - Drug Profile
    • cobimetinib fumarate - Drug Profile
    • COTI-2 - Drug Profile
    • dacomitinib - Drug Profile
    • Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
    • Edotreotide Labeled Yttrium 90 - Drug Profile
    • etirinotecan pegol - Drug Profile
    • ETS-2101 - Drug Profile
    • Gene Therapy for Brain Cancer - Drug Profile
    • HMPL-813 - Drug Profile
    • ipilimumab - Drug Profile
    • irbinitinib - Drug Profile
    • irinotecan hydrochloride + TBio-02 - Drug Profile
    • KML-001 - Drug Profile
    • LEQ-506 - Drug Profile
    • lorlatinib - Drug Profile
    • lucanthone hydrochloride - Drug Profile
    • MDNA-55 - Drug Profile
    • Monoclonal Antibody to Inhibit CD47 for Kidney Transplantation, Cardiovascular Disease and Oncology - Drug Profile
    • NBM-01 - Drug Profile
    • neratinib - Drug Profile
    • nimotuzumab - Drug Profile
    • NMSE-973 - Drug Profile
    • NOV-202 - Drug Profile
    • ORIL-007 - Drug Profile
    • PB-357 - Drug Profile
    • PBT-519 - Drug Profile
    • pelareorep - Drug Profile
    • pracinostat - Drug Profile
    • PT-112 - Drug Profile
    • RAD-1901 - Drug Profile
    • radretumab - Drug Profile
    • RRX-001 - Drug Profile
    • siomycin A - Drug Profile
    • SL-301 - Drug Profile
    • SL-302 - Drug Profile
    • Small Molecule for Brain Cancer and Malignant Glioma - Drug Profile
    • Small Molecule for Glioblastomas - Drug Profile
    • Small Molecule to Agonize GPR55 for Oncology - Drug Profile
    • Small Molecules to Inhibit Hedgehog Signaling for Medulloblastoma - Drug Profile
    • THR-317 - Drug Profile
    • TPI-287 - Drug Profile
    • transcrocetinate sodium - Drug Profile
    • Trilexium - Drug Profile
    • TTL-1177 - Drug Profile
    • ubidecarenone - Drug Profile
    • Vaccine for Cancer - Drug Profile
    • Vaccine for Glioblastoma Multiforme - Drug Profile
    • veliparib - Drug Profile
    • VMY-1103 - Drug Profile
    • vocimagene amiretrorepvec + flucytosine ER - Drug Profile
    • ZW-39 - Drug Profile
  • Brain Cancer - Recent Pipeline Updates
  • Brain Cancer - Dormant Projects
  • Brain Cancer - Discontinued Products
  • Brain Cancer - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Brain Cancer, H2 2015
  • Number of Products under Development for Brain Cancer - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Development by Companies, H2 2015 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Brain Cancer - Pipeline by 2-BBB Medicines BV, H2 2015
  • Brain Cancer - Pipeline by AbbVie Inc., H2 2015
  • Brain Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H2 2015
  • Brain Cancer - Pipeline by AngioChem Inc., H2 2015
  • Brain Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H2 2015
  • Brain Cancer - Pipeline by BeiGene(Beijing) Co.,Ltd, H2 2015
  • Brain Cancer - Pipeline by Berg, LLC, H2 2015
  • Brain Cancer - Pipeline by biOasis Technologies Inc., H2 2015
  • Brain Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015
  • Brain Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2015
  • Brain Cancer - Pipeline by Cavion LLC, H2 2015
  • Brain Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2015
  • Brain Cancer - Pipeline by CureFAKtor Pharmaceuticals, LLC, H2 2015
  • Brain Cancer - Pipeline by Diffusion Pharmaceuticals LLC, H2 2015
  • Brain Cancer - Pipeline by e-Therapeutics Plc, H2 2015
  • Brain Cancer - Pipeline by Exelixis, Inc., H2 2015
  • Brain Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
  • Brain Cancer - Pipeline by Hutchison MediPharma Limited, H2 2015
  • Brain Cancer - Pipeline by Komipharm International Co., Ltd., H2 2015
  • Brain Cancer - Pipeline by Lipocure Ltd., H2 2015
  • Brain Cancer - Pipeline by Medicenna Therapeutics, Inc, H2 2015
  • Brain Cancer - Pipeline by MEI Pharma, Inc., H2 2015
  • Brain Cancer - Pipeline by NatureWise Biotech & Medicals Corporation, H2 2015
  • Brain Cancer - Pipeline by Nektar Therapeutics, H2 2015
  • Brain Cancer - Pipeline by Nerviano Medical Sciences S.r.l., H2 2015
  • Brain Cancer - Pipeline by Novartis AG, H2 2015
  • Brain Cancer - Pipeline by Novogen Limited, H2 2015
  • Brain Cancer - Pipeline by Oncology Research International Limited, H2 2015
  • Brain Cancer - Pipeline by Oncolytics Biotech Inc., H2 2015
  • Brain Cancer - Pipeline by Oncothyreon Inc., H2 2015
  • Brain Cancer - Pipeline by Pfizer Inc., H2 2015
  • Brain Cancer - Pipeline by Philogen S.p.A., H2 2015
  • Brain Cancer - Pipeline by Phosplatin Therapeutics LLC, H2 2015
  • Brain Cancer - Pipeline by Prana Biotechnology Limited, H2 2015
  • Brain Cancer - Pipeline by Progenics Pharmaceuticals, Inc., H2 2015
  • Brain Cancer - Pipeline by Puma Biotechnology, Inc., H2 2015
  • Brain Cancer - Pipeline by Radius Health, Inc., H2 2015
  • Brain Cancer - Pipeline by Sanofi, H2 2015
  • Brain Cancer - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015
  • Brain Cancer - Pipeline by Stemline Therapeutics, Inc., H2 2015
  • Brain Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
  • Brain Cancer - Pipeline by Tocagen Inc., H2 2015
  • Brain Cancer - Pipeline by ViraTherapeutics GmbH, H2 2015
  • Brain Cancer - Pipeline by Zymeworks Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Brain Cancer Therapeutics - Recent Pipeline Updates, H2 2015
  • Brain Cancer - Dormant Projects, H2 2015
  • Brain Cancer - Dormant Projects (Contd..1), H2 2015
  • Brain Cancer - Dormant Projects (Contd..2), H2 2015
  • Brain Cancer - Dormant Projects (Contd..3), H2 2015
  • Brain Cancer - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Brain Cancer, H2 2015
  • Number of Products under Development for Brain Cancer - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top